CIRRUSHCM: A multiple-dose phase 2 study of safety, tolerability, and effects on hemodynamics and functional capacity of the novel cardiac sarcomere modulator EDG-7500 in hypertrophic cardiomyopathy
18 May 2025 (10:58 - 11:06)
Organised by: 
Slides
About the speaker
University of Pennsylvania, Philadelphia (United States of America)
20 More presentations in this session
Professor U. Bavendiek (Hannover, DE)
Access the full session
The Event
Heart Failure 2025
18 May 2025
10:58 CET
You may be interested in
Congress Presentation
Congress Session
